A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100)

Clinical trial NCT03600883 · COMPLETED

Trial details

NCT number: NCT03600883
Sponsor: Amgen
Status: COMPLETED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

KRAS p.G12C Mutant Advanced Solid Tumors

Start date: 2018-08-27
Primary completion: 2026-05-29
Enrollment: 713

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.